Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:


Last Updated: January 26, 2020

DrugPatentWatch Database Preview

Patent: 9,447,173

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

Summary for Patent: 9,447,173
Title:Human antibodies to respiratory syncytial virus F protein and methods of use thereof
Abstract: The present invention provides fully human antibodies that bind to respiratory syncytial virus F protein, compositions comprising the antibodies and methods of use. The antibodies of the invention are useful for preventing fusion of the virus with the cell membrane and preventing cell to cell spread of the virus, thereby providing a means of preventing the infection, or treating a patient suffering from the infection and ameliorating one or more symptoms or complications associated with the viral infection. The antibodies may also be useful for diagnosis of an infection by RSV.
Inventor(s): Gurnett-Bander; Anne (Carmel, NY), Perez-Caballero; David (Briarwood, NY), Sivapalasingam; Sumathi (Brooklyn, NY), Duan; Xunbao (Maple Glen, PA), MacDonald; Douglas (New York, NY)
Assignee: Regeneron Pharmaceuticals, Inc. (Tarrytown, NY)
Application Number:14/207,797
Patent Claims:see list of patent claims

Details for Patent 9,447,173

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Medimmune SYNAGIS palivizumab VIAL 103770 002 1998-06-19   Start Trial Regeneron Pharmaceuticals, Inc. (Tarrytown, NY) 2033-03-14 RX search
Medimmune SYNAGIS palivizumab VIAL 103770 001 1998-06-19   Start Trial Regeneron Pharmaceuticals, Inc. (Tarrytown, NY) 2033-03-14 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.